Clinical trial
V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
NCT00109343 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00109343 |
|---|---|
| Title | V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) |
| Official title | An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Measles, Mumps, Rubella, Varicella |
| Intervention type | Biological |
| Interventions | Comparator: ProQuad™ (V221), Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine) |
| Enrollment | 1,027 |
| Start date | Mar 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 27, 2005 |
| Last update posted | Apr 12, 2017 |
At a glance
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: